SM
ECYT

Sabby Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Sabby Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-159
Closed -$97 – 302
2014
Q3 		$97 Sell
159
-1,001
-86% -$6.84K ﹤0.01% 233
2014
Q2 		$764K Buy
1,160
+1,006
+653% +$11.3K 0.03% 171
2014
Q1 		$367K Buy
154
+47
+44% +$681 0.02% 189
2013
Q4 		$114K Hold
107
– – 0.01% 197
2013
Q3 		$143K Buy
+107
New +$1.69K 0.01% 182

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's ECYT Position: Q4 2015 in Review

Sabby Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2015, closing a stake of 26,423 shares — an estimated $121K sold.

Sabby Management first reported a position in ECYT in Q4 2013 and held it in 3 quarters. The position peaked at $597K in Q4 2013. 102 funds tracked by Wall St. Rank hold ECYT as of Q4 2015.

  • Sabby Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Sabby Management sold 26,423 Endocyte, Inc. Common Stock shares in Q4 2015, an estimated $121K.
  • Sabby Management first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 3 quarters.
  • Sabby Management's Endocyte, Inc. Common Stock position peaked at $597K in Q4 2013.
  • 102 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.